Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

Abstract Background Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid h...

Full description

Bibliographic Details
Main Authors: Mitsuru Ichii, Katsuhito Mori, Daichi Miyaoka, Mika Sonoda, Yoshihiro Tsujimoto, Shinya Nakatani, Tetsuo Shoji, Masanori Emoto
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Nephrology
Subjects:
Renal anemia
Roxadustat
Thyroid stimulating hormone (TSH)
Thyroid hormone receptor
Case report
Online Access:https://doi.org/10.1186/s12882-021-02304-2

Internet

https://doi.org/10.1186/s12882-021-02304-2

Similar Items